Alogliptin and Mavorixafor: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Mavorixafor
Alogliptin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects
Interaction Deep Dive
Coadministration of mavorixafor (P-gp substrate) with a P-gp inhibitor may increase mavorixafor exposure and may increase the risk of mavorixafor related adverse reactions. Monitor more frequently for mavorixafor adverse reactions and reduce the mavorixafor daily dosage by steps of 100 mg, if necessary, but not to a dose less than 200 mg1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport of mavorixafor
Literature reports
1 report — tap to read
a) In a drug interaction study in healthy subjects, the systemic exposure of mavorixafor (CYP3A4 substrate and P-gp substrate) following concomitant administration of a single dose of mavorixafor 200 mg (0.5 times the recommended dosage for adult and adolescent patients 12 years and older weighing over 50 kg) with 200 mg itraconazole (strong CYP3A4 inhibitor and P-gp inhibitor) dosed to steady state was similar to the mavorixafor systemic exposure from a single dose of mavorixafor 400 mg administered alone. These results suggest an approximate increase in mavorixafor exposure by 2-fold due to itraconazole 1.
Common questions
Can I take Alogliptin and Mavorixafor together?
Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Alogliptin and Mavorixafor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Alogliptin or Mavorixafor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XOLREMDI(TM) oral capsules, mavorixafor oral capsules. X4 Pharmaceuticals, Inc. (Per FDA), Boston, MA, 2024. DailyMed
Keep reading about Mavorixafor
Keep reading about Alogliptin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist